Get the Stockscreener App
0.6849
0.45%
-0.0031
Kronos Bio Inc stock is traded at $0.6849, with a volume of 310.03K.
It is down -0.45% in the last 24 hours and down -22.18% over the past month.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
See More
Previous Close:
$0.688
Open:
$0.6761
24h Volume:
310.03K
Relative Volume:
0.66
Market Cap:
$41.76M
Revenue:
-
Net Income/Loss:
$-112.67M
P/E Ratio:
-0.3512
EPS:
-1.95
Net Cash Flow:
$-79.26M
1W Performance:
+0.54%
1M Performance:
-22.18%
6M Performance:
-24.15%
1Y Performance:
-29.39%
1-Day Range:
$0.6751
$0.69
1-Week Range:
$0.6675
$0.70
52-Week Range:
$0.65
$1.60
Kronos Bio Inc Stock (KRON) Company Profile
Name
Kronos Bio Inc
Sector
Industry
Phone
(650) 781-5200
Address
1300 S. EL CAMINO REAL, SAN MATEO
Compare KRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRON
Kronos Bio Inc
|
0.6849 | 42.98M | 0 | -112.67M | -79.26M | -1.95 |
|
ONC
Beigene Ltd Adr
|
240.18 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.85 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.76 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.68 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Kronos Bio Inc Stock (KRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-14-24 | Downgrade | TD Cowen | Buy → Hold |
| Sep-14-22 | Initiated | Berenberg | Buy |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jun-24-21 | Initiated | H.C. Wainwright | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Goldman | Buy |
| Nov-03-20 | Initiated | Jefferies | Buy |
| Nov-03-20 | Initiated | Piper Sandler | Overweight |
View All
Kronos Bio Inc Stock (KRON) Latest News
Shareholders Filed a Lawsuit Against Kronos Bio for Merger Disclosure Failures - TradingView
Kronos Bio ($KRON) Misleading Merger Proxy and Insider Enrichment Case - TradingView
Kronos Bio Shareholder Says Sale Unfairly Benefits Execs - Law360
Kronos Bio, Board Sued by Shareholder Over Concentra Buyout Deal - Bloomberg Law News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders - GlobeNewswire Inc.
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView
Kronos Bio discovers p300 inhibitors - BioWorld MedTech
Weekly CEO Buys Highlight - GuruFocus
Concentra Biosciences Agrees to Acquire Kronos Bio - Contract Pharma
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc.KRON - Business Wire
KRON Shares Experience Decline in Value - knoxdaily.com
why Kronos Bio Inc [KRON] is a Good Choice for Investors After New Price Target of $1.00 - dbtnews.com
Kronos shares slump on Concentra takeover news - The Pharma Letter
Kronos Bio (KRON) to Merge with Concentra Biosciences in $0.57 P - GuruFocus
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc.KRON - PR Newswire
Struggling Peninsula biotech with Gilead lineage is latest purchase for activist investorSan Francisco Business Times - The Business Journals
Now Is The Time To Build A Position In Kronos Bio Inc (NASDAQ:KRON) - Marketing Sentinel
KRON’s Stock Market Labyrinth: Navigating 2023’s Gains and Declines - investchronicle.com
Kronos Bio Enters Deal to be Acquired by Concentra Biosciences; Shares Fall - marketscreener.com
Today’s watch list includes Kronos Bio Inc (NASDAQ:KRON) stock - uspostnews.com
Kronos Bio stock hits 52-week low at $0.68 amid market challenges - Investing.com India
After hunt for alternatives, Kronos Bio selects Tang Capital’s Concentra for a deal - Endpoints News
Kronos Bio (KRON) to be Acquired by Concentra Biosciences in Strategic Merger | KRON Stock News - GuruFocus
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders - The Joplin Globe
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders - The Joplin Globe
Concentra To Acquire Kronos Bio - Nasdaq
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right - The Manila Times
Kronos Bio agrees to Concentra Biosciences acquisition - Investing.com
Kronos Bio Enters into Agreement to Be Acquired by - GlobeNewswire
Kronos Bio (KRON) Projected to Announce Quarterly Earnings on Thursday - Defense World
Renaissance Technologies LLC Has $1.11 Million Position in Kronos Bio, Inc. (NASDAQ:KRON) - Defense World
Kronos Bio ends lease early, pays $1.4 million settlement - Investing.com Australia
Kronos Bio ends lease early, pays $1.4 million settlement By Investing.com - Investing.com Canada
Kronos Bio Announces Lease Termination Agreement - TipRanks
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors - The Manila Times
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
Kronos Bio Reports 2024 Financial Results - TipRanks
Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Kronos Bio Full Year 2024 Earnings: US$1.43 loss per share (vs US$1.95 loss in FY 2023) - Yahoo Finance
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Kronos Bio earnings missed by $0.17, revenue fell short of estimates - Investing.com Canada
Kronos Bio Inc (KRON) Q4 2024 Earnings: EPS Misses at -$0.43, Re - GuruFocus.com
Kronos Bio, Inc. SEC 10-K Report - TradingView
China Revives Its Carbon Credit Market: Price Swings & Future Outlook - The Globe and Mail
Navigating the U.S. Planting Season with Enhanced Risk Management - The Globe and Mail
Kronos Bio Inc Stock (KRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):